Capricor Therapeutics Inc (NASDAQ:CAPR) reported its fourth quarter and full year 2017 financial results. It also provided a corporate update.
Analyst spotlights a compelling path forward for DMD program and looks to key catalysts in fourth quarter.
On Tuesday, Capricor Therapeutics, Inc. (NASDAQ:CAPR) was granted FDA Rare Pediatric Disease Designation for CAP-1002, the company’s treatment for Duchenne muscular dystrophy (DMD) and …
Netflix, Inc. (NASDAQ:NFLX) shares are shooting up in Tuesday’s trading session following the release of very impressive earnings results for the second quarter.
It’s a very rewarding trading day for investors in Capricor Therapeutics Inc (NASDAQ:CAPR) with shares up nearly 130%, making the stock Wall Street’s …